Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Oncology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
LaNova MedicinesChina - Shanghai
2 programs2
LM-108 in combination with ToripalimabPhase 3Monoclonal Antibody1 trial
LM-302Phase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
LaNova MedicinesLM-108 in combination with Toripalimab
LaNova MedicinesLM-302
Clinical Trials (2)
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Start: Apr 2026Est. completion: Sep 2028
Phase 3Not Yet Recruiting
LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
Start: Jun 2024Est. completion: Dec 2026
Phase 3Active Not Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
3h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
3h ago
Office Administrator
SystImmune
3h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
3h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
3h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
3h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
Monoclonal Antibody is the dominant modality (100% of programs)
1 companies competing in this space